Malcolm Mitchell

Malcolm Mitchell

Auto-generated profile, based on publicly available information

Malcolm Mitchell

Lilly Research Laboratories, Indianapolis, Indiana

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2010 in BMC Psychiatry
Verified
Journal Article
Open access
PDF file
DMDavid P McDonnell
David P McDonnell
HDHolland C Detke
Holland C Detke
RBRichard F Bergstrom
Richard F Bergstrom
PKPrajakti Kothare
Prajakti Kothare
JJJason Johnson
Jason Johnson
MMMalcolm I Mitchell
Malcolm I Mitchell
Olanzapine long-acting injection (LAI) is a salt-based depot antipsychotic combining olanzapine and pamoic acid. The slow intramuscular dissolution of this practically insoluble salt produces an extended release of olanzapine lasting up to 4 weeks. However, in a small number of injections (< 0.1%), patients experienced symptoms suggestive of olanzapine overdose, a phenomenon that has been termed "post-injection delirium/sedation syndrome" (PDSS). The authors conducted a series of parallel investigations into the possible reasons PDSS events occur. Healthcare providers involved in the PDSS cases were queried for clinical information around the events. Plasma samples from patients experiencing PDSS were collected when possible (12/30 cases) and olanzapine concentrations compared with the known pharmacokinetic profile for olanzapine LAI. Product batches and used vials from the PDSS cases were evaluated for compliance with established manufacturing standards and/or possible user error. Because this depot formulation depends upon slow dissolution at the intramuscular injection site, in-vitro experiments were conducted to assess solubility of olanzapine pamoate in various media. Injection administrators reported no unusual occurrences during the injection. No anomalies were found with the product batches or the remaining suspension in the used vials. Olanzapine concentrations during PDSS events were higher than the expected 5-73 ng/mL range, with concentrations exceeding 100 ng/mL and in some cases reaching >600 ng/mL during the first hours after injection but then returning to the expected therapeutic range within 24 to 72 hours. Solubility and dissolution rate of olanzapine pamoate were also found to be substantially greater in plasma than in other media such as those approximating the environment in muscle tissue. Manufacturing irregularities, improper drug reconstitution, and inappropriate dosing were ruled out as possible causes of PDSS. In-vitro solubility and in-vivo pharmacokinetic investigations suggest that PDSS is related to exposure of the injected product to a substantial volume of blood. This exposure is most likely the result of unintended partial intravascular injection or blood vessel injury during the injection (occurring even with proper injection technique) with subsequent seepage of the medication into the vasculature, which would produce higher than intended olanzapine concentrations and symptoms consistent with PDSS. ClinicalTrials.gov ID; URL: http://http//www.clinicaltrials.gov/ : NCT00094640, NCT00088478, NCT00088491, NCT00088465, and NCT00320489

1 December 2013 in Clinical Therapeutics
Verified
Journal Article
Closed access
MMMalcolm Mitchell
Malcolm Mitchell
PKPrajakti Kothare
Prajakti Kothare
RBRichard Bergstrom
Richard Bergstrom
FZFangyi Zhao
Fangyi Zhao
KJKai Yu Jen
Kai Yu Jen
DMDavid McDonnell
David McDonnell

19 March 2012 in BMC Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
PKPrajakti A Kothare
Prajakti A Kothare
MSMary E Seger
Mary E Seger
JNJustin Northrup
Justin Northrup
KMKenneth Mace
Kenneth Mace
MMMalcolm I Mitchell
Malcolm I Mitchell
HLHelle Linnebjerg
Helle Linnebjerg
Consistent with its effect on gastric emptying, exenatide, an injectable treatment for type 2 diabetes, may slow the absorption rate of concomitantly administered oral drugs resulting in a decrease in maximum concentration (Cmax). This study evaluated the drug interaction potential of exenatide when administered adjunctively with oral contraceptives, given their potential concomitant use.

1 June 2006 in Clinical Therapeutics
Verified
Journal Article
Closed access
MMMalcolm Mitchell
Malcolm Mitchell
RRRobert Riesenberg
Robert Riesenberg
MBMohammad A. Bari
Mohammad A. Bari
EMEva Marquez
Eva Marquez
DKDarcie Kurtz
Darcie Kurtz
PCPatrizia Cavazzoni
Patrizia Cavazzoni